Literature DB >> 35721605

Hyperkalemia and Metabolic Acidosis Occur at a Higher eGFR in Sickle Cell Disease.

Santosh L Saraf1, Vimal K Derebail2, Xu Zhang1, Roberto F Machado3, Victor R Gordeuk1, James P Lash4, Jane Little5.   

Abstract

Background: People with sickle cell disease (SCD) have an elevated estimated glomerular filtration rate (eGFR) compared with the general population, and this may alter the usual creatinine-based eGFR cutoffs for which physiologic evidence of kidney dysfunction is apparent. This study aimed to identify eGFR thresholds for hyperkalemia and metabolic acidosis in patients with SCD.
Methods: This was a cross-sectional analysis of 733 patients with severe (hemoglobin SS or Sβ 0-thalassemia) SCD genotype, 238 patients with moderate (hemoglobin SC or Sβ +-thalassemia) SCD genotype, and 1333 age- and sex-matched African Americans from the National Health and Nutrition Examination Survey (NHANES). The prevalence rates of hyperkalemia and metabolic acidosis were compared by eGFR category. Cutoffs for hyperkalemia and metabolic acidosis were determined using generalized additive models.
Results: Hyperkalemia and metabolic acidosis were more common in those with severe SCD genotype (13% and 21%, respectively) compared with the NHANES (0.3% and 5%, respectively); the prevalence rates in the moderate SCD genotype were intermediate for hyperkalemia (3%) and metabolic acidosis (11%). The proportion of patients with hyperkalemia and metabolic acidosis progressively increased with lower eGFR category in both SCD genotype groups. The eGFR thresholds for hyperkalemia and metabolic acidosis were higher in the severe (85 and 91 ml/min per 1.73 m2, respectively) and moderate (52 and 102 ml/min per 1.73 m2, respectively) SCD genotypes compared with the NHANES (34 and 46 ml/min per 1.73 m2). Conclusions: We demonstrate that hyperkalemia and metabolic acidosis are more common and occur at higher eGFR values in patients with SCD compared with age- and sex-matched African Americans, including in eGFR ranges considered to be normal. Future studies using redefined creatinine-based eGFR thresholds for abnormal kidney function may identify high-risk patients for earlier intervention strategies and referral for specialized renal care in SCD.
Copyright © 2022 by the American Society of Nephrology.

Entities:  

Keywords:  acidosis; bicarbonate; chronic kidney disease; estimated glomerular filtration rate; hyperkalemia; kidney disease; potassium; sickle cell disease

Mesh:

Substances:

Year:  2022        PMID: 35721605      PMCID: PMC9136900          DOI: 10.34067/KID.0006802021

Source DB:  PubMed          Journal:  Kidney360        ISSN: 2641-7650


  29 in total

1.  Hyporeninemic hypoaldosteronism in sickle cell disease.

Authors:  M Yoshino; R Amerian; N Brautbar
Journal:  Nephron       Date:  1982       Impact factor: 2.847

Review 2.  Metabolic acidosis and malnutrition-inflammation complex syndrome in chronic renal failure.

Authors:  Kamyar Kalantar-Zadeh; Rajnish Mehrotra; Denis Fouque; Joel D Kopple
Journal:  Semin Dial       Date:  2004 Nov-Dec       Impact factor: 3.455

3.  Glomerular hyperfiltration in adult sickle cell anemia: a frequent hemolysis associated feature.

Authors:  Jean-Philippe Haymann; Katia Stankovic; Pierre Levy; Virginie Avellino; Pierre-Louis Tharaux; Emmanuel Letavernier; Gilles Grateau; Laurent Baud; Robert Girot; François Lionnet
Journal:  Clin J Am Soc Nephrol       Date:  2010-02-25       Impact factor: 8.237

4.  New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race.

Authors:  Lesley A Inker; Nwamaka D Eneanya; Josef Coresh; Hocine Tighiouart; Dan Wang; Yingying Sang; Deidra C Crews; Alessandro Doria; Michelle M Estrella; Marc Froissart; Morgan E Grams; Tom Greene; Anders Grubb; Vilmundur Gudnason; Orlando M Gutiérrez; Roberto Kalil; Amy B Karger; Michael Mauer; Gerjan Navis; Robert G Nelson; Emilio D Poggio; Roger Rodby; Peter Rossing; Andrew D Rule; Elizabeth Selvin; Jesse C Seegmiller; Michael G Shlipak; Vicente E Torres; Wei Yang; Shoshana H Ballew; Sara J Couture; Neil R Powe; Andrew S Levey
Journal:  N Engl J Med       Date:  2021-09-23       Impact factor: 176.079

5.  Serum potassium and adverse outcomes across the range of kidney function: a CKD Prognosis Consortium meta-analysis.

Authors:  Csaba P Kovesdy; Kunihiro Matsushita; Yingying Sang; Nigel J Brunskill; Juan J Carrero; Gabriel Chodick; Takeshi Hasegawa; Hiddo L Heerspink; Atsushi Hirayama; Gijs W D Landman; Adeera Levin; Dorothea Nitsch; David C Wheeler; Josef Coresh; Stein I Hallan; Varda Shalev; Morgan E Grams
Journal:  Eur Heart J       Date:  2018-05-01       Impact factor: 29.983

6.  Albuminuria and renal function in homozygous sickle cell disease: observations from a cohort study.

Authors:  Joanne Thompson; Marvin Reid; Ian Hambleton; Graham R Serjeant
Journal:  Arch Intern Med       Date:  2007-04-09

7.  Increased tissue acid mediates a progressive decline in the glomerular filtration rate of animals with reduced nephron mass.

Authors:  Donald E Wesson; Jan Simoni
Journal:  Kidney Int       Date:  2009-02-04       Impact factor: 10.612

Review 8.  Chronic hyperkalemia in non-dialysis CKD: controversial issues in nephrology practice.

Authors:  Luca De Nicola; Luca Di Lullo; Ernesto Paoletti; Adamasco Cupisti; Stefano Bianchi
Journal:  J Nephrol       Date:  2018-06-07       Impact factor: 3.902

9.  Determining glomerular filtration rate in homozygous sickle cell disease: utility of serum creatinine based estimating equations.

Authors:  Monika R Asnani; O'Neil Lynch; Marvin E Reid
Journal:  PLoS One       Date:  2013-07-19       Impact factor: 3.240

10.  Serum Potassium, Sodium, and Chloride Levels in Sickle Cell Disease Patients and Healthy Controls: A Case-Control Study at Korle-Bu Teaching Hospital, Accra.

Authors:  Charles Antwi-Boasiako; Yaw A Kusi-Mensah; Charles Hayfron-Benjamin; Robert Aryee; Gifty Boatemaah Dankwah; Kwawukume Lim Abla; Ebenezer Owusu Darkwa; Felix Abekah Botchway; Eric Sampene-Donkor
Journal:  Biomark Insights       Date:  2019-09-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.